InvestWiser

Gabather AB (publ)

GABANasdaq StockholmHealthcareMarket value 11 m SEK
0.02SEK +2.2%
last day · Price as of 18 November 2026

The answer first

Does Gabather beat the market?

No, Gabather has not beaten the market over the last year.

Gabather−31.3%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 6% of Nordic stocks

    • Quality59
    • Value1
    • Trend8

    No. 174 of 195 in healthcare

Max for seven days

Follow Gabather with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Gabather

From today, at a price of 0.02 SEK. Write why you follow Gabather, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Gabather

Your first answer is free, no account needed.

Do you own Gabather, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Gabather and a few more. Free, no card.

Past year against the exchange and Super Stock
Gabather−31.3%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Gabather has fallen 31.3% over the past year, including dividends.
  • Overall, Gabather ranks better than 6% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 98.1%. The price is 99.9% below its peak now.

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

6

Quality, value and trend together. Better than 6% of Nordic stocks.

No. 174 of 195 in healthcare

Quality59
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 108 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.00
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−341.5%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value1
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 194 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity7.3
  • P/SPrice divided by salesnegative earnings
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend8
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 162 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−42.5%
  • 6 months−56.2%
  • 9 months−37.4%
  • 12 months−31.3%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−18.6%
3 years, per year
−69.5%
5 years, per year
−55.6%
10 years, per year
−47.7%
Largest fall, 3 years
−98.1%
From a peak to the bottom
From the peak now
−99.9%
How far the price is from the peak
Volatility, 1 year
122.1%
How much the price swings over a year
Beta, 1 year
0.45
How much the price moves when the market moves

Return with dividends reinvested.

About Gabather

Gabather AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 2 employees.

Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. The company focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer's disease, schizophrenia, and major depressive disorders. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje, Sweden.

See the full analysis of Gabather.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market